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Implantation of a left ventricular assist device and the hub-and-spoke
system in treating acute cardiogenic shock: Who survives?
Aftab R. Kherani, MD, Faisal H. Cheema, MD, Mehmet C. Oz, MD, Jennifer M. Fal, BA, Jeffrey A. Morgan, MD,
Veli K. Topkara, David A. Wilson, BA, Deon W. Vigilance, MD, Mauricio J. Garrido, MD, and Yoshifumi Naka, MD, PhD,
New York, NY
We have established a regional referral network that facilitates the transfer ofpatients in cardiogenic shock to our center for definitive management. This“hub-and-spoke” network has proven to be effective in treating this criticallyill population. Postcardiotomy shock complicates 2% to 6% of cardiac
procedures.1 The incidence of cardiogenic shock following acute myocardial infarction
(AMI) is 5% to 15%.2 Medical management composed of inotropes and pressors with or
without intra-aortic balloon pump support represents the standard of care in treating these
patients. The advent of left ventricular assist devices (LVADs) introduced a surgical option
for cases refractory to medical management. This study delineates who survives in this
population and how the postcardiotomy setting impacts device placement.
Methods
This was a retrospective review looking at the short-term outcome of the 46 patients
transferred from 22 spoke institutions to 1 tertiary hub center between October 1993 and May
2002 who underwent implantable LVAD insertion at the hub. Patients were placed into 1 of
3 groups:
1. Group A: patients were status post-AMI and did not undergo surgical revascularization
[coronary artery bypass grafting (CABG)] but instead were managed medically. Two
patients additionally underwent extracorporeal ventricular assist device implantation at
the spoke hospital (1 LVAD, 1 biventricular assist device).
2. Group B: patients were status post-AMI, had cardiogenic shock, and underwent
emergency surgical revascularization at the spoke hospital prior to transfer.
3. Group C: patients had postcardiotomy shock after an elective cardiac procedure at the
spoke facility.
Groups B and C distinguish themselves from A in that the former underwent traditional
cardiac procedures on cardiopulmonary bypass at spoke hospitals either resulting in postcar-
diotomy shock or in an effort to treat it.
All statistical analysis employed SPSS version 10.0.1 (Chicago, Ill).
Results
The mean age of the 46 patients (33 men, 13 women) was 54.2  10.1 years (range
17.8-66.4). There were 9 patients in group A, 18 in group B, and 19 in group C. The mean
age of group A was 58.3  7.0, in group B was 49.3  9.5, and in group C was 56.8  10.5
(ANOVA P  .03). At the time of arrival to the hub, markers of end-organ function
(creatinine and prothrombin time) were comparable between the groups (Table 1).
Overall survival to discharge was 56.5% (26/46). Group A enjoyed a survival advantage
over group C (P  .039). When group A was compared with groups B and C combined,
statistical significance was nearly achieved (P  .057). Table 1 summarizes.
Kaplan-Meier survival (Figure 1) revealed no significant differences between the groups
(log-rank P value: .23), although the trend did appear to favor group A. Three patients were
successfully weaned off LVAD support; another 20 underwent transplantation.
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Discussion
Cardiogenic shock is the leading cause of death in patients having
an AMI. The majority of these patients (71.7%) die in the hospital;
in the absence of shock, mortality is significantly lower (12.0%, P
 .001).2 The randomized SHOCK (Should We Emergently Re-
vascularize Occluded Coronaries for Cardiogenic Shock) trial
compared early revascularization (CABG or angioplasty) in pa-
tients with cardiogenic shock with medical management. Emer-
gency revascularization did not significantly reduce mortality at 30
days, but after 6 months, a significant survival benefit was ob-
served in these patients.3
Postcardiotomy shock similarly is associated with a poor prog-
nosis, with only a quarter of all patients surviving to discharge.
Ventricular assist devices have demonstrated effectiveness in treat-
ing these patients, and to this end, hub-and-spoke networks play an
important role. Survival to discharge in our population was over
50%.
These patient groups (A, B, and C) are unique; thus, we
understand that we are comparing “apples and oranges” to some
extent and that our results speak only for the short-term. Yet even
in this small, retrospective study, avoidance of non-LVAD surgical
intervention at the spoke hospital generally improved survival to
discharge, suggesting that the postcardiotomy setting may com-
promise subsequent ventricular assist device implantation. Thus,
we advocate a larger-scale, prospective, randomized trial compar-
ing ventricular assist device intervention with traditional revascu-
larization in treating acute cardiogenic shock to clarify the poten-
tially important role of ventricular assist devices in treating this
population. Cost should be 1 factor examined to address how
cost-effective maximal intervention is at treating these critically ill
patients.
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TABLE 1. Survival to discharge and markers of end-organ function in the three populations
Group A Group B Group C
Group A vs
group B
(P value)
Group A vs
group C
(P value)
Group B vs
group C
(P value)
Group A vs
group B & C
(P value)
Survival to discharge 8/9(88.8%) 10/18(55.5%) 8/19(42.1%) .19 .039 .52 .057
Creatinine on arrival
at hub (mg/dL)
1.9 0.9 2.0 1.4 2.0 1.7 .81 .76 .93 .74
Prothrombin time on
arrival at hub (s)
19.1 5.1 18.9 6.2 28.7 37.0 .77 .28 .25 .33
Figure 1. Hub-and-spoke (long-term implantable ventricular assist device). Kaplan-Meier survival of the 3
populations.
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